戈利木单抗作为一种新型的抗肿瘤坏死因子（TNF）-α制剂，已在国外开展了经典的诱导缓解研究试验和维持缓解研究试验。临床试验已证实其对中重度溃疡性结肠炎的治疗有较好效果，具有起效快、临床缓解率和黏膜愈合率高以及不良反应少等优点。主要对戈利木单抗已开展的经典临床研究试验、疗效和安全性以及存在的问题和解决办法的研究进展进行综述，以期为临床安全合理使用戈利木单抗提供参考。

Golimumab is a novel anti-tumor necrosis factor (TNF)-α preparation, and the classic induced remission study and maintenance mitigation research trial of golimumab have been carried out overseas. Golimumab has been proved to be effective in the treatment of refractory or severe ulcerative colitis with rapid onset, high clinical remission rate, high mucosal healing rate, and less adverse reactions. Research progress on classic clinical trial, curative effect, security, existing problems, and solution of golimuritan are reviewed in this paper, in order to provide references for safe and appropriate use of golimumab in clinic.